FIG 5.

The anti-HBV action of tazarotene is partially through RARβ. (A) PHH cells infected with HBV were treated with tazarotene in the presence or absence of the RARα antagonist Ro41-5253. The supernatant was collected for HBsAg and HBeAg analysis after 6 days of treatment. (B) PHH cells infected with HBV were treated with multiple doses of tazarotene in the presence or absence of the RARβ antagonist LE135. The supernatant was collected for HBsAg and HBeAg analysis after 6 days of treatment, and cell viability was determined by CCK-8. (C and D) PHH cells infected with HBV were treated with multiple doses of BMS-189453 (C) or Ro41-5253 (D), as indicated. The cell culture medium was collected for HBsAg and HBeAg analysis after 6 days of treatment.